Stockreport

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics, Inc.  (BBOT) 
PDF BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Anno [Read more]